Inmed pharmaceuticals receives nasdaq notification regarding minimum bid price compliance

Vancouver, british columbia--(newsfile corp. - september 22, 2023) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced the company received written notice from the listing qualifications department staff of the nasdaq capital market ("nasdaq") dated september 19, 2023, notifying that the closing bid price of the company's common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on the nasdaq under nasdaq listing rule 5550(a)(2). in accordance with applicable nasdaq procedures, the company has a period of 180 calendar days following the receipt of the written notice mentioned above to cure the deficiency and regain compliance.
INM Ratings Summary
INM Quant Ranking